CAS No.
1234423-95-0(Unlabeled)
Smiles
ClC1=C(C2)C([C@H](C3=CC([S](NCCOCCOCCNC(NC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])NC(NCCOCCOCCN[S](=O)(C4=CC([C@H](C5)C6=CC(Cl)=CC(Cl)=C6CN5C)=CC=C4)=O)=O)=O)(=O)=O)=CC=C3)CN2C)=CC(Cl)=C1
Storage Condition
Refer MSDS for complete information.
IUPAC Name
(S)-N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl-12,12,13,13,14,14,15,15-d8)bis(3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzenesulfonamide)
References
"Labonte, E. D., et al.: J. Am. Soc. Nephrol. 26, 1138 (2015); Spencer, A. G. and Greasley, P. J.: Curr Opin Nephrol Hypertens 24, 410 (2015)"
Synonyms
(S)-N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl-12,12,13,13,14,14,15,15-d8)bis(3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzenesulfonamide)
Application Notes
"17-[[[3-[(4S)-6,8-Dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]-N-[2-[2-[2-[[[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]ethoxy]ethoxy]ethyl]-8-oxo-12,15-dioxa-2,7,9-triazaheptadecanamide-d8 (deuterium labeled) is an inhibitor of sodium/hydrogen exchanger isoform 3 (NHE3), which is a major absorptive sodium transporter. It has therapeutic potential for lowering gastrointestinal sodium absorption and improving fluid overload-related symptoms, such as hypertension and proteinuria, in patients with CKD."
Hazard Compound
Refer MSDS for complete information.
Overview
"17-[[[3-[(4S)-6,8-Dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]-N-[2-[2-[2-[[[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]ethoxy]ethoxy]ethyl]-8-oxo-12,15-dioxa-2,7,9-triazaheptadecanamide-d8 (deuterium labeled) is an inhibitor of sodium/hydrogen exchanger isoform 3 (NHE3), which is a major absorptive sodium transporter. It has therapeutic potential for lowering gastrointestinal sodium absorption and improving fluid overload-related symptoms, such as hypertension and proteinuria, in patients with CKD."
